We are live on ! Find out more
AQST icon

Aquestive Therapeutics

56 hedge funds and large institutions have $101M invested in Aquestive Therapeutics in 2019 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

643% more capital inflows, than outflows

Capital inflows: $24.3M | Capital outflows: $3.27M

300% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

60% more funds holding

Funds holding: 35 → 56 (+21)

0.23% more ownership

Funds ownership: 54.25% → 54.47% (+0.23%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

Holders
56
Holders Change
+21
Holders Change %
+60%
% of All Funds
1.1%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
28
Increased
12
Reduced
12
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AQST Hedge Fund Activity: Q4 2019 in Review

56 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2019, worth a combined $101M — up 134% from $43.2M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new AQST positions and 7 closed out — a net gain of 21 holders — while 12 added to existing stakes and 12 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $3.84M. The largest seller was Massachusetts Financial Services, exiting entirely with an estimated $934K sold.

  • 56 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2019, up from 35 in Q3 2019.
  • Funds reported $101M of Aquestive Therapeutics stock for Q4 2019, up 134% quarter-over-quarter.
  • 28 funds opened new Aquestive Therapeutics positions in Q4 2019 and 7 closed out, a net change of +21 holders.
  • The largest Aquestive Therapeutics buyer in Q4 2019 was Opaleye Management, an estimated $3.84M added.
  • The largest Aquestive Therapeutics seller in Q4 2019 was Massachusetts Financial Services, an estimated $934K sold.

Based on aggregated 13F filings for Q4 2019.